Zai Lab expects return to meaningful revenue growth in 2027
ZLAB•Zai Lab expects meaningful revenue growth to resume in 2027 as patient access expands for key products. Third-quarter 2026 net product revenue rose 1.7% sequentially to $107.6 million, total revenue was $108.2 million, and a $250 million private investment will support global zoci development.
1. Revenue and financing
Zai Lab expects a return to meaningful revenue growth in 2027 as patient access expands for key products. Third-quarter 2026 net product revenue rose 1.7% sequentially to $107.6 million, while total revenue reached $108.2 million. A $250 million private investment in public equity financing will support global zoci development while maintaining operating discipline.
